165 related articles for article (PubMed ID: 37046787)
1. The Immune Checkpoint Receptor CD96: A Local and Systemic Immune Modulator in Oral Cancer?
Trumet L; Weber M; Hahn A; Kunater L; Geppert C; Glajzer J; Struckmeier AK; Möst T; Lutz R; Kesting M; Ries J
Cancers (Basel); 2023 Apr; 15(7):. PubMed ID: 37046787
[No Abstract] [Full Text] [Related]
2. PD1 expression and correlation with its ligands in oral cancer specimens and peripheral blood.
Wehrhan F; Weber M; Baran C; Agaimy A; Büttner-Herold M; Kesting M; Ries J
J Craniomaxillofac Surg; 2021 Feb; 49(2):118-125. PubMed ID: 33358116
[TBL] [Abstract][Full Text] [Related]
3. Beyond PD-L1-Identification of Further Potential Therapeutic Targets in Oral Cancer.
Weber M; Lutz R; Olmos M; Glajzer J; Baran C; Nobis CP; Möst T; Eckstein M; Kesting M; Ries J
Cancers (Basel); 2022 Apr; 14(7):. PubMed ID: 35406584
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression in tumor tissue and peripheral blood of patients with oral squamous cell carcinoma.
Weber M; Wehrhan F; Baran C; Agaimy A; Büttner-Herold M; Preidl R; Neukam FW; Ries J
Oncotarget; 2017 Dec; 8(68):112584-112597. PubMed ID: 29348848
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of PD-L2 expression in patients with oral squamous cell carcinoma-A comparison to the PD-L1 expression profile.
Weber M; Wehrhan F; Baran C; Agaimy A; Büttner-Herold M; Kesting M; Ries J
Cancer Med; 2019 Mar; 8(3):1124-1134. PubMed ID: 30659749
[TBL] [Abstract][Full Text] [Related]
6. Does surgery affect systemic immune response? a perioperative analysis of TGF-β, IL-8 and CD45RO.
Trumet L; Ries J; Ivenz N; Sobl P; Wehrhan F; Lutz R; Kesting M; Weber M
Front Oncol; 2023; 13():1307956. PubMed ID: 38162490
[TBL] [Abstract][Full Text] [Related]
7. CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma.
Zhang S; Yan Q; Wei S; Feng X; Xue M; Liu L; Cui J; Zhang Y
Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Aug; 132(2):202-209. PubMed ID: 34034998
[TBL] [Abstract][Full Text] [Related]
8. Immune and Clinical Features of
Zhang Q; Zhong H; Fan Y; Liu Q; Song J; Yao S; Cao F
Front Bioeng Biotechnol; 2020; 8():592. PubMed ID: 32695752
[TBL] [Abstract][Full Text] [Related]
9. Postoperative Changes in Systemic Immune Tolerance Following Major Oncologic versus Minor Maxillofacial Surgery.
Trumet L; Ries J; Sobl P; Ivenz N; Wehrhan F; Lutz R; Kesting M; Weber M
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568571
[TBL] [Abstract][Full Text] [Related]
10. CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma.
Liu F; Huang J; He F; Ma X; Fan F; Meng M; Zhuo Y; Zhang L
Sci Rep; 2020 Jul; 10(1):10768. PubMed ID: 32612110
[TBL] [Abstract][Full Text] [Related]
11. Importance of the PD-1/PD-L1 Axis for Malignant Transformation and Risk Assessment of Oral Leukoplakia.
Ries J; Agaimy A; Wehrhan F; Baran C; Bolze S; Danzer E; Frey S; Jantsch J; Möst T; Büttner-Herold M; Wickenhauser C; Kesting M; Weber M
Biomedicines; 2021 Feb; 9(2):. PubMed ID: 33669300
[TBL] [Abstract][Full Text] [Related]
12. Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer.
Wang Y; Wang C; Qiu J; Qu X; Peng J; Lu C; Zhang M; Zhang M; Qi X; Li G; Hua K
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288463
[TBL] [Abstract][Full Text] [Related]
13.
Chen Z; Chen Q; Li S; Tu S; Chen Q; Wang A
Ann Transl Med; 2022 Feb; 10(3):144. PubMed ID: 35284546
[TBL] [Abstract][Full Text] [Related]
14. Advances in therapeutic targeting of immune checkpoints receptors within the CD96-TIGIT axis: clinical implications and future perspectives.
Farhangnia P; Akbarpour M; Yazdanifar M; Aref AR; Delbandi AA; Rezaei N
Expert Rev Clin Immunol; 2022 Dec; 18(12):1217-1237. PubMed ID: 36154551
[TBL] [Abstract][Full Text] [Related]
15. The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer.
Aydın EM; Demir TD; Seymen N; Said SS; Oktem-Okullu S; Tiftikci A; Cicek B; Tokat F; Tozun N; Ince U; Sezerman U; Sayi-Yazgan A
Immunol Lett; 2021 Nov; 239():1-11. PubMed ID: 34363898
[TBL] [Abstract][Full Text] [Related]
16. CD8+ and CD163+ infiltrating cells and PD-L1 immunoexpression in oral leukoplakia and oral carcinoma.
Stasikowska-Kanicka O; Wągrowska-Danilewicz M; Danilewicz M
APMIS; 2018 Sep; 126(9):732-738. PubMed ID: 30160018
[TBL] [Abstract][Full Text] [Related]
17. Dynamic contrast-enhanced MRI as a predictor of programmed death ligand-1 expression in patients with oral squamous cell carcinoma.
Tekiki N; Fujita M; Okui T; Kawai H; Oo MW; Kawazu T; Hisatomi M; Okada S; Takeshita Y; Barham M; Nagatsuka H; Yanagi Y; Asaumi JI
Oncol Lett; 2021 Nov; 22(5):778. PubMed ID: 34594419
[TBL] [Abstract][Full Text] [Related]
18. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
19. Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes.
Chen XJ; Tan YQ; Zhang N; He MJ; Zhou G
Pathol Res Pract; 2019 Jun; 215(6):152418. PubMed ID: 31027907
[TBL] [Abstract][Full Text] [Related]
20. An Inhibitory Role for Human CD96 Endodomain in T Cell Anti-Tumor Responses.
Wang CQ; Choy FC; Sanny A; Murakami T; Tan AH; Lam KP
Cells; 2023 Jan; 12(2):. PubMed ID: 36672244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
